Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology
+$0.03 today
- Market cap
- $103.50M
- Beta
- 0.42
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.19
Volume 1.28M
Average 0.21M
TLSA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Tiziana Life Sciences LtdNASDAQ: TLSA
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income remains negative
Q4 FY2025 net income was -$12.8M, compared with -$7.21M a year earlier.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$9.45M (+48.7%) for the fiscal year ending Dec 2026, a step up from the -55.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$12.8M— QoQ
- Last fiscal yearDec 2025
- -$18.43M-55.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -77.5% | — | — |
| 1 year | -55.4% | +48.7% | +104.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (18.43M) USD
- Year-over-year change
- -55.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (18.43M) | -55.4% |
| FY2024 | 2024-12-31 | (11.86M) | +46.9% |
| FY2023 | 2023-12-31 | (22.36M) | -18.2% |
| FY2022 | 2022-12-31 | (18.92M) | +40.1% |
| FY2021 | 2021-12-31 | (31.59M) | — |
Net Income vs competitors
How TLSA compares with its peers on the latest reported figures
- TLSA's FY2025 net income of -$18.43M is the 3rd highest of the 9 companies compared; the peer median is -$52.67M.
- Its year-over-year change of -55.4% is the 7th highest of 9, against a peer median of -24.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | -$4.71M | +72.0% | — | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | -$9.67M | -44.2% | — | — |
| FY2025 | -$18.43M | -55.4% | — | — | |
| LTM Mar 2026 | -$21.13M | -23.3% | — | 266.1% | |
| LTM Mar 2026 | -$34.98M | -67.4% | — | — | |
| LTM Mar 2026 | -$70.36M | -26.1% | — | 44.8% | |
| LTM Mar 2026 | -$113.22M | +48.4% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.81M | -519.4% | — | — |
| LTM Mar 2026 | -$124.13M | +44.6% | — | — | |
| Peer median (excluding TLSA) | -$52.67M | -24.7% | — | 155.4% | |
Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 234K |
| Gross Profit | 0 | 0 | 0 | 0 | (234K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 17.82M | 15.92M | 10.25M | 5.23M | 10.28M |
| Selling, General & Admin | 1.15M | 4.76M | 8.26M | 10.28M | 10.77M |
| Operating Expenses | 36.93M | 17.93M | 22.73M | 15.79M | 21.05M |
| Depreciation & Amortization | 190.2K | 62.68K | 121.34K | 124K | 234K |
| EBITDA | (35.53M) | (18.85M) | (21.66M) | (16.62M) | (21.05M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.93M) | (17.93M) | (22.73M) | (15.79M) | (21.28M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.46M | 814K | 19K |
| Interest Expense | 237.41K | 8.6K | 12.64K | 6K | 18K |
| Other Income / Expenses | 967.18K | (996.78K) | 937.89K | (952K) | 2.85M |
| Income Before Tax | (35.96M) | (18.92M) | (21.79M) | (16.75M) | (18.43M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (4.37M) | 0 | 567.54K | (4.88M) | 0 |
| Net Income | (31.59M) | (18.92M) | (22.36M) | (11.86M) | (18.43M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.64) | (0.36) | (0.42) | (0.22) | (0.32) |
| EPS (Diluted) | (0.64) | (0.36) | (0.42) | (0.22) | (0.32) |
| Weighted Avg Shares | 48.97M | 50.76M | 50.76M | 53.34M | 59.14M |
| Weighted Avg Shares (Diluted) | 48.97M | 50.76M | 50.76M | 53.34M | 59.14M |
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.